Angle (AGL)

[WickedLester]

More interesting research:

https://www.investegate.co.uk/angle-plc ... 00070047N/

PARSORTIX ENABLES MOLECULAR CHARACTERISATION OF CTCS ISOLATED FROM FROZEN SAMPLES IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND SARCOMA

Dr Giulia Bertolini and Dr Vera Cappelletti, Department of Experimental Oncology, National Cancer Institute of Milan, commented:

"This study demonstrates the feasibility of CTC analyses in cryopreserved PBMCs and represents an advance in blood sample management for CTC studies, allowing for a better selection of informative time points to longitudinally investigate tumor progression/response to therapy thereby enabling retrospective studies."

[WickedLester]

And straight after FDA approval a partnership with a major American Urology group:

https://www.investegate.co.uk/angle-plc ... 00071584N/

PARTNERSHIP ESTABLISHED WITH A MAJOR UNITED STATES UROLOGY GROUP TO CONDUCT CLINICAL STUDIES IN PROSTATE CANCER AND AS A POTENTIAL ROUTE TO MARKET

[WickedLester]

There's an interesting article on the FT.com website today (I don't know if it's in the print edition) for anyone that's a subscriber. Apparently they've already received lots of interest from the US since getting FDA approval for Parsotix.

[torata]

There's an interesting article on the FT.com website today (I don't know if it's in the print edition) for anyone that's a subscriber. Apparently they've already received lots of interest from the US since getting FDA approval for Parsotix.

Goggling 'FT' and 'UK start-up Angle draws interest for newly approved cancer test' should get one-time access through the firewall.

torata

[WickedLester]

I know we appear to be in a bear market, particularly for technology and I know that large scale commercialisation of Parsotix is still some years away, but boy did I think the price would be higher than this a few days after they got FDA approval!

[pje16]

Angle wins cancer monitoring contract for Parasortix system

(Alliance News) - Angle PLC on Wednesday said it has secured further business with its "first large scale pharma services" customer.

The Surrey, England-based medical diagnostics company expects the additional contract to be worth up to USD1.2 million over a "multi-year period".

The customer, which Angle didn't name, is a pharmaceutical company developing numerous cancer drugs, with annual revenue over USD1 billion, it said. The customer will use Angle's Parasortix system in longitudinal monitoring of patients with unresectable solid tumours in a phase IB immunoncology trial.

Parasortix isolates circulating tumour cells from the blood which can aid in the diagnosis, characterisation and monitoring of cancer. In late May, it received approval from the US Food & Drug Administration for use in metastatic breast cancer patients.

Angle anticipates that if the trial is successful, the contract could progress to phase II studies and much larger phase III studies.

"The additional contract from our first large-scale pharma customer, as well as ongoing discussions with multiple potential new customers, validates Angle's belief that longitudinal monitoring of CTCs is a highly attractive proposition for the pharma industry looking for new insights in cancer drug trials," said Chief Executive Officer Andrew Newland.

Shares in Angle were down 0.8% at 92.25 pence each in London on Wednesday morning.

source
https://www.ii.co.uk/secure/my-news-fee ... 7558089500
(login required)

[WickedLester]

Some very interesting research published today. It was widely reported in the press too.

https://www.investegate.co.uk/angle-plc ... 00082063Q/

[b}BREAKTHROUGH RESEARCH WITH PARSORTIX REVEALS SPREAD OF BREAST CANCER ACCELERATES DURING SLEEP[/b]

Professor Nicola Aceto, ETH Zurich, commented:

"We have worked with the Parsortix system for over four years now. The ability to reliably harvest CTCs, CTC clusters and CTC-WBC clusters has allowed us to develop an understanding of cancer metastasis not previously possible. In this study we observed a striking and unexpected pattern of CTC generation dynamics in both patients with breast cancer and preclinical models, highlighting that most spontaneous CTC intravasation events occur during sleep. Further, we demonstrate that rest-phase CTCs are highly prone to metastasize, whereas CTCs generated during the active phase are devoid of metastatic ability. These findings suggest the need for time-controlled approaches for the characterisation and treatment of breast cancer and the investigation of new drug targets."

[torata]

Some very interesting research published today. It was widely reported in the press too.

https://www.investegate.co.uk/angle-plc ... 00082063Q/

[b}BREAKTHROUGH RESEARCH WITH PARSORTIX REVEALS SPREAD OF BREAST CANCER ACCELERATES DURING SLEEP[/b]

Professor Nicola Aceto, ETH Zurich, commented:

"We have worked with the Parsortix system for over four years now. The ability to reliably harvest CTCs, CTC clusters and CTC-WBC clusters has allowed us to develop an understanding of cancer metastasis not previously possible. In this study we observed a striking and unexpected pattern of CTC generation dynamics in both patients with breast cancer and preclinical models, highlighting that most spontaneous CTC intravasation events occur during sleep. Further, we demonstrate that rest-phase CTCs are highly prone to metastasize, whereas CTCs generated during the active phase are devoid of metastatic ability. These findings suggest the need for time-controlled approaches for the characterisation and treatment of breast cancer and the investigation of new drug targets."

[I have to resort to inappropriate humour to hide the tears of frustration with this share... But its time, and the benefit to society from it, will come eventually.]

It seems Neil from the Young Ones was presciently right, then.
https://www.youtube.com/watch?v=KEITpehWiXk

torata

[WickedLester]

Has the interest in this share faded along with the share price?

The interims are out today and on first reading the prospects appear better than ever post FDA approval.

https://www.investegate.co.uk/angle-plc ... 00120792B/

Outlook

· Pharma services business momentum - discussions in progress with more than twenty biopharma companies offering a pipeline of opportunities for new contracts as we move through the end of this year and into 2023. Almost all potential customers are interested in bespoke assay development

· Global sales and distribution network being established with first contracts in negotiation and initial seeding of instruments anticipated

· Accreditation of clinical laboratories in final stages offering ability to offer validated tests for both pharma services and patient management in coming months

· New product roll-out to accelerate with a pipeline of sample-to-answer imaging and molecular solutions being finalised for offer to customers

· Numerous discussions in progress with potential partners including medtech companies, downstream assay providers and clinical laboratories regarding selected Parsortix based assays

· Continued investment in clinical studies to provide clinical evidence to support long term growth

Secondly the results of their Ovarian cancer study have been published and they appear very encouraging.

https://www.investegate.co.uk/angle-plc ... 00080755B/

Parsortix test successful in discriminating malignant and benign abnormal pelvic masses from a simple blood draw for detection of ovarian cancer

Best in class results indicate the potential to reduce both false positives and false negatives by 50% or more



I remain happy to hold and believe this company has an excellent chance of being valued at a multiple of today's price in a couple of years time if progress continues in this fashion. It's my largest investment by amount invested and the fall in price this year is a major driver of why my performance this year has been so poor. Parsotix really does appear to have the ability to revolutionise cancer diagnosis and care and save money to boot and the market opportunity is huge.

My big fear is that with the price so low that a predator comes in with a low offer and fatigued investors accept.

[torata]

Parsotix really does appear to have the ability to revolutionise cancer diagnosis and care and save money to boot and the market opportunity is huge.

Just an aside, but the nematode c. elegans can detect a number of early-stage cancers with high reliability through a single drop of urine.

Here's a Nature article on them being used for breast cancer:
https://www.nature.com/articles/s41598-021-96613-z

In short, they run away(?) from urine that doesn't have cancer, and congregate towards it if it does.
It's already been commercialized (although there are no effective barriers to entry, no IP)

I think simple, fast, non-invasive detection of cancers, especially at early stage, is going to be huge. For Angle, it's now got to get picked up by the US hospitals, which requires education, and it's got to do the same in other countries. It may be that the only way to do that is to be bought out or to collaborate in a similar way to BioNtech.

But I also hold

torata

Couldn't resist this edit: Here's a Japanese ad with some all singing, all dancing nematodes
https://www.youtube.com/watch?v=Sh-SIuR4teI

[WickedLester]

There has been more news from the company recently which appears very encouraging.

https://www.investegate.co.uk/angle-plc ... 00099856E/

I recently doubled up my shareholding at around the current price, I wouldn't be at all surprised if this company gets taken over in the foreseeable future and if that does happen I hope to do pretty well. I've certainly read nothing which has dented my belief that liquid biopsy is going to be big in the future and Angle are one of the leaders in it.

[WickedLester]

There's an interesting looking IPO planned for next month.

https://clsc-docs.s3-eu-west-2.amazonaw ... V-2022.pdf

It's worth having a browse through the whole document but if you look at page 26, company B looks very much like AGL.

Who knows, we could be welcoming another new institutional investor in the new year.

I particularly like their comment that the company could be generating its own market cap in EBIT in 3-5 years. If it is Angle and it comes true I'll be one very happy bunny indeed.

[WickedLester]

I don't know if i'm the only one here still holding, but it's been painful since FDA approval was received. I bought more shares at 54p and then bought some more today at a touch over 30p after a profit warning sent the shares tumbling.

https://www.investegate.co.uk/angle-plc ... 00067310L/

I remain of the belief that this company is destined for great things and that a delay will not stop them from being worth much, much more in 5 years time assuming they don't get taken over first.

The only worry I have is that they find some finding without diluting the shareholders too much at this price and on that front they have appointed a new NED who looks to have been chosen to take care of this.

https://www.investegate.co.uk/angle-plc ... 01017313L/

I'm planning on buying more tomorrow, I just can't believe that an FDA approved test, in a huge market, that has first mover advantage, can save money and enable better treatment of patients and hopefully therefore better outcomes for cancer sufferers isn't worth more than £50m to someone.

[WickedLester]

Happy New Year Fools.

This is my first post in here for a while and my first on this board for really quite a long time. To be honest the share price had fallen so far and there'd been so little news that I'd started to wonder whether I'd got this one wrong. As people do, I had decided not to sell because I'd lost such a large percentage of my money anyway and I was still quite convinced it was likely to work out in time, I was just worried about funding in such a brutal bear market.

Anyway, On 4th January there was an an announcement that seems to have got the market really quite excited.

https://www.londonstockexchange.com/new ... s/16274813

BREAKTHROUGH CLINICAL RESULTS PROVIDE A UNIQUE INSIGHT INTO THE PROGRESSION OF EACH PATIENT'S CANCER


I reckon this is really important news and I'm much more confident than I have been for some time that my cows are finally going to come home. It looks like Parsotix could be the biggest breakthrough in cancer diagnosis and treatment since Chemotherapy.

I really was thinking about betting the farm on AGL, I decided when I first started investing that I wanted something much bigger than my ancestors small holding.

I'm hoping this one will make me feel like a Pearly King, even if I have to roll out the barrel on my own, I'm going Dahn to Margit, you can keep your Costa Brava and all of that Palaver, I'm now well chuffed this one ain't going to take a Turner for the worst, I'll stay in a bed and breakfast, It seems Eminently suitable, I just know when I visit Dreamland I'm going to make out like a bandit and not ride the Big Dipper.

Everyone knows the adage 'A Fool And His Money Aren't Easily Parted'.

Sleep tight fools, I'm taking a break, when I'm in the mood I can smoke like Dot Cotton, she just never did it with buckets of Coke.

Lester

[torata]

Yes, the news tripled the share price (for a day anyway), so I'm no longer in the 90% down club!

I can see the amazing use for the technology, but I suspect nobody's heard of it. They aren't going to rake it in with their Lab services, and although there are a couple of mentions of having now set up global distributors in their latest report, there are no links to them on their website, and no specifics about who they are, so that doesn't inspire confidence. (And getting the right distributors around the world is such a risky business.) The contracts they have are with pharma companies that seem pretty minor (Artios Pharma, anyone?).

I think commercialization is going to be an uphill struggle for them unless they get a big contract with a big hitter, either a pharma, a CRO or a distributor with clout and resources, or possibly some kind of national health service.

But Harrison Ford used to put up shelves for people in Hollywood.

torata